Transient viral load increases in HIV-infected children in the UK and Ireland: What do they mean?

Antiviral Therapy

Volumn 12, Issue 6, 2007, Pages 949-956

  Lee, Katherine J ^a   Shingadia, Delane ^b   Pillay, Deenan ^c   Walker, A Sarah ^a   Riordan, Andrew ^d   Menson, Esse ^e   Duong, Trinh ^f   Tudor Williams, Gareth ^g   Gibb, Diana M ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; IRELAND; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SEX DIFFERENCE; UNITED KINGDOM; VIREMIA; VIRUS LOAD; VIRUS MUTATION;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; GREAT BRITAIN; HIV; HIV INFECTIONS; HUMANS; INFANT; IRELAND; MALE; VIRAL LOAD; VIREMIA;

EID: 34848812656     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viraemia (blips) and drug resistance in patients receiving HAART. JAMA 2005; 297:817-829.
2. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viraemia with combined HIV therapy. JAMA 2001; 286:171-179.
3. Mira JA, Macias J, Nogales C, et al. Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir Ther 2002; 7:251-256.
4. Sklar PA, Ward DJ, Baker RK, et al. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS 2002; 16:2035-2041.
5. Cohan Stuart JW, Wensing AM, Kovacs C, et al. Transient relapses ('blips') of plasma HIV RNA levels during haart are associated with drug resistance. J Acquir Immune Defic Syndr 2001; 28:105-113.
6. Macias J, Palomares JC, Mira JA, et al. Transient rebounds of HAV plasma viraemia are associated with the emergence of drug resistant mutations in patients on highly active antiretroviral therapy. J Infect 2005; 51:195-200.
7. Easterbrook PJ, Ives N, Waters A, et al. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to <400 copies/ml. AIDS 2002; 16:1521-1527.
8. Greub G, Cozzi-Lepri A, Ledergerber B, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002; 16:1967-1969.
9. van Rossum AM, Fraaij PLA, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2006; 2:93-102.
10. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1999; 18:682-689.
11. Reddington C, Cohen J, Bildillo A, et al. Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J 2000; 19:1148-1153.
12. Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003; 327:1019-1025.
13. Royston P. Multiple imputation of missing data. Stata J 2004; 4:227-241.
14. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999; 18:681-694.
15. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995; 51:524-532.
16. Cane P, Chrystie I, Dunn D, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331:1368-1371.
17. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 2005; 13:125-131.
18. Moore AL, Youle M, Lipman M, et al. Raised viral load in patients with viral suppression in highly active antiretroviral therapy: transient increase or treatment failure? AIDS 2002; 16:615-618.
19. Di Mascio M, Markowiz M, Louie M, et al. Dynamics of intermittent viraemia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection. J Virol 2004; 78:10566-10573.
20. Percus JK, Percus OE, Markowiz M, et al. The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy. Bull Math Biol 2003; 65:263-277.
21. De Rossi A, Walker AS, De Forni D, et al. Relationships between changes in thymic emigrants and cell-associated HIV-1 DNA in HIV-1 infected children initiating antiretroviral therapy. Antivir Ther 2006; 10:63-71.